Baird Financial Group
IOVA icon

Baird Financial Group’s Iovance Biotherapeutics IOVA Stock Holding History

Baird Financial Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$925K Buy
222,340
+23,800
+12% +$90.4K ﹤0.01% 1346
2026
Q1 		$697K Buy
198,540
+41,000
+26% +$131K ﹤0.01% 1379
2025
Q4 		$430K Sell
157,540
-4,035
-2% -$9.34K ﹤0.01% 1527
2025
Q3 		$351K Sell
161,575
-28,270
-15% -$66.8K ﹤0.01% 1580
2025
Q2 		$327K Sell
189,845
-6,000
-3% -$14.9K ﹤0.01% 1553
2025
Q1 		$652K Hold
195,845
– – ﹤0.01% 1310
2024
Q4 		$1.45M Buy
195,845
+2,000
+1% +$18.5K ﹤0.01% 1069
2024
Q3 		$1.82M Buy
193,845
+57,245
+42% +$542K ﹤0.01% 988
2024
Q2 		$1.1M Buy
136,600
+125,800
+1,165% +$1.35M ﹤0.01% 1138
2024
Q1 		$160K Hold
10,800
– – ﹤0.01% 1696
2023
Q4 		$87.8K Buy
+10,800
New +$56.5K ﹤0.01% 1683
2022
Q4 		– Sell
-19,055
Closed -$183K – 1726
2022
Q3 		$183K Sell
19,055
-179
-0.9% -$2.06K ﹤0.01% 1623
2022
Q2 		$212K Sell
19,234
-8,311
-30% -$109K ﹤0.01% 1681
2022
Q1 		$459K Buy
27,545
+995
+4% +$15.4K ﹤0.01% 1446
2021
Q4 		$507K Sell
26,550
-4,517
-15% -$99.4K ﹤0.01% 1463
2021
Q3 		$766K Buy
+31,067
New +$732K ﹤0.01% 1310
2021
Q2 		– Sell
-7,325
Closed -$232K – 1757
2021
Q1 		$232K Sell
7,325
-34,561
-83% -$1.43M ﹤0.01% 1596
2020
Q4 		$1.94M Buy
41,886
+8,625
+26% +$342K 0.01% 815
2020
Q3 		$1.09M Buy
33,261
+4,233
+15% +$130K ﹤0.01% 918
2020
Q2 		$797K Buy
29,028
+17,983
+163% +$591K ﹤0.01% 1000
2020
Q1 		$331K Buy
+11,045
New +$293K ﹤0.01% 1182

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Baird Financial Group's IOVA Position: Q2 2026 in Review

Baird Financial Group increased its Iovance Biotherapeutics (IOVA) stake by 12% in Q2 2026, buying an estimated $90.4K and bringing the position to 222,340 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #1346.

Baird Financial Group first reported a position in IOVA in Q1 2020 and has held it in 21 quarters since. The position peaked at $1.94M in Q4 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Baird Financial Group held 222,340 shares of Iovance Biotherapeutics worth $925K as of Q2 2026.
  • Baird Financial Group bought 23,800 Iovance Biotherapeutics shares in Q2 2026, an estimated $90.4K.
  • Iovance Biotherapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1346 holding.
  • Baird Financial Group first reported a position in Iovance Biotherapeutics in Q1 2020 and has held it in 21 quarters since.
  • Baird Financial Group's Iovance Biotherapeutics position peaked at $1.94M in Q4 2020.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.